Compound Primer
Retatrutide as a Research Peptide: What the Trials Say
Updated · 3 cited sources · ResearchChem Research Team
Short answer: Retatrutide (LY3437943) is an investigational single-peptide triple agonist of the GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. It is not an approved drug anywhere; US phase 3 trials began in 2023 and are ongoing. Published phase 2 trials in NEJM (obesity) and The Lancet (type 2 diabetes) reported large reductions in body weight and HbA1c versus placebo. ResearchChem supplies synthetic retatrutide to U.S.-based researchers in four strengths; each lot ships with a Certificate of Analysis on request.
What is retatrutide?
Retatrutide, also written as LY3437943, is a single 39-amino-acid peptide engineered to act as an agonist at three different receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor [1]. That makes it the first triple-agonist peptide to reach late-stage clinical trials, after an earlier generation of dual agonists such as tirzepatide, which binds GIP and GLP-1 only.
Compared with the dual GIP/GLP-1 agonist tirzepatide, the design hypothesis is that adding glucagon-receptor activity recruits an additional energy-expenditure pathway while keeping the appetite and insulin-sensitivity effects of the GIP/GLP-1 side. Whether that hypothesis holds up in phase 3 is still being tested. For the mechanism behind the dual-agonist starting point, see semaglutide vs tirzepatide mechanism.
What have the published trials reported?
Two phase 2 trials have been published in major journals.
In obesity, Jastreboff and colleagues enrolled 338 adults with a BMI of 30 or more (or 27 or more with at least one weight-related condition) in a 48-week randomized, double-blind, placebo-controlled trial. At week 48, the least-squares mean percent change in body weight was −8.7% with retatrutide 1 mg, −17.1% with 4 mg (starting dose 2 mg), −22.8% with 8 mg (starting dose 2 mg), −17.5% with 8 mg (starting dose 4 mg), and −24.2% with 12 mg (starting dose 2 mg), versus −2.1% with placebo. The most common adverse events in the retatrutide arms were gastrointestinal: nausea, diarrhea, vomiting, and constipation [1].
In type 2 diabetes, Rosenstock and colleagues enrolled 281 adults with HbA1c between 7.0% and 10.5% on metformin or no background therapy in a 36-week randomized, double-blind, placebo- and active-controlled trial comparing retatrutide with placebo and with dulaglutide 1.5 mg. At week 36, HbA1c change from baseline was −0.43% with placebo, −1.39% with dulaglutide, −1.60% with retatrutide 4 mg, −2.02% with 8 mg, and −2.16% with 12 mg. Mean body weight change was +0.9 kg with placebo, −2.0 kg with dulaglutide, and −3.2 kg, −7.9 kg, −10.4 kg, and −16.9 kg across the retatrutide 0.5/4/8/12 mg groups [2].
Both trials are randomized clinical results published under peer review; neither is a regulatory approval. Retatrutide remains investigational in all markets.
Where does retatrutide stand in the U.S. pipeline?
Retatrutide is not an FDA-approved drug. It is an investigational molecule in the Eli Lilly pipeline. The company's TRIUMPH phase 3 program began in 2023 and includes TRIUMPH-1 (obesity, NCT05929066), TRIUMPH-2 (obesity with type 2 diabetes, NCT05929079), TRIUMPH-3 (obesity with established cardiovascular disease, NCT05882045), and TRIUMPH-4 (obesity with knee osteoarthritis, NCT05936151), with primary completion dates in 2026–2027 [3]. Readouts and any subsequent NDA/BLA filing are yet to come.
No compounded retatrutide is lawful in the U.S.: the compound is not on the FDA's 503A or 503B bulks lists. For research, the material is handled under the "research use only" (RUO) category: the vial is supplied for in-vitro and animal research, not for human administration or compounding.
What should a retatrutide COA show?
| Field | What it tells you | What to check |
|---|---|---|
| Lot number | Which production run the results belong to | Matches the lot printed on your vial |
| Sequence or formula | Which molecule was tested | Matches retatrutide (LY3437943), 39-residue peptide |
| Identity (MS) | Measured molecular mass vs theoretical mass | Observed mass close to the theoretical ~4,731 Da |
| Purity (HPLC) | Share of UV-absorbing material that is the main peak | Percentage plus the chromatogram, column, and wavelength |
| Peptide content | How much of the powder weight is peptide vs counter-ions | Method stated, e.g. amino acid analysis |
| Endotoxin (optional) | Bacterial endotoxin level | Method named, e.g. LAL / USP <85> |
| Methods and limits | How each result was produced and what counts as a pass | An acceptance criterion next to every result |
| Lab, date, sign-off | Who tested it and when | Lab name, analysis date, analyst or QA signature |
A deeper walkthrough of each field is in how to read a peptide COA. The HPLC number is the one most commonly misread; HPLC peptide purity explained covers what it does and does not report.
How do U.S. researchers source retatrutide?
For U.S.-based research use, a supplier should ship domestically (no international customs hold), supply a lot-specific Certificate of Analysis on request, and label every vial with the standard RUO compliance line. Storage and reconstitution instructions should be consistent with a lyophilized peptide: unopened vials stored at −20 °C, reconstituted with bacteriostatic water for in-vitro use.
ResearchChem carries retatrutide in four strengths — 10 mg ($60), 20 mg ($100), 30 mg ($130), and 40 mg ($160) — synthesized and released against a per-lot HPLC and mass-spec specification, shipped from the U.S. The physical vial carries the real 40×20 mm compliance sticker: "RESEARCH USE ONLY · NOT FOR HUMAN USE". The lot-specific COA is sent on request — email [email protected] with the lot number from the vial.
Frequently asked questions
Is retatrutide approved in the United States?
No. Retatrutide is investigational. Eli Lilly began the TRIUMPH phase 3 program in 2023; no FDA approval has been granted, and the compound is not on the 503A or 503B compounding bulks lists.
What receptors does retatrutide act on?
Three: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. That three-way agonist design separates it from dual GIP/GLP-1 agonists such as tirzepatide.
What did the phase 2 obesity trial report?
At 48 weeks, mean body-weight reductions ranged from −8.7% at the 1 mg dose to −24.2% at the 12 mg dose, versus −2.1% with placebo. The most common adverse events were gastrointestinal.
What did the phase 2 type 2 diabetes trial report?
At 36 weeks, HbA1c reductions from baseline reached −2.16% in the retatrutide 12 mg arm, versus −0.43% with placebo and −1.39% with dulaglutide 1.5 mg. Body-weight reductions were larger than with dulaglutide at every retatrutide dose above 0.5 mg.
Does ResearchChem ship retatrutide inside the United States?
Yes. Retatrutide ships from the U.S. in four strengths (10 mg, 20 mg, 30 mg, 40 mg). Every vial carries the RUO compliance line, and the Certificate of Analysis for your lot is sent on request.
Cited studies
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.. N Engl J Med. 389(6):514-526 (2023). PubMed 37366315 DOI
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.. Lancet. 402(10401):529-544 (2023). PubMed 37385280 DOI
- Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1).. ClinicalTrials.gov, NCT05929066 (2023). Source
Related compounds
- Retatrutide — Tri-Agonist Peptide
Keep reading
Research use only. ResearchChem products are laboratory reagents for in-vitro research. They are not for human or veterinary consumption and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published research for educational purposes and is not medical advice.